Welcome to our dedicated page for Proto Labs SEC filings (Ticker: PRLB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Proto Labs, Inc. filings document the regulatory record for an NYSE-listed digital manufacturing company that produces custom parts for prototyping, testing, bridge production, short-run production, and end-use applications. Its SEC disclosures cover operating results, revenue by service activity, non-GAAP measures, cash-flow commentary, and business updates related to CNC machining, digital platforms, and manufacturing capacity.
PRLB filings also include Form 8-K material-event reports for earnings releases and executive leadership changes, amendments to previously furnished results information, and proxy materials covering board matters, executive compensation, equity awards, shareholder voting items, and governance. The company’s filings identify its common stock under the PRLB ticker on the New York Stock Exchange.
Proto Labs (PRLB) insider Oleg Ryaboy filed a Form 144 notice covering the potential sale of 695 common shares through Morgan Stanley Smith Barney LLC on the NYSE, with an aggregate market value of $34,686.76 and an approximate sale date of 11/25/2025.
The 695 shares were acquired on 05/14/2024 through an Employee Stock Purchase Plan and paid for in cash. The filing also reports that during the past three months, Ryaboy sold 9,710 common shares on 11/07/2025 for gross proceeds of $471,629.27. By signing the notice, he represents that he is not aware of any undisclosed material adverse information about Proto Labs.
Proto Labs (PRLB) has a Form 144 notice for a proposed sale of 3,048 shares of its common stock. The shares are planned to be sold through Morgan Stanley Smith Barney LLC on the NYSE, with an indicated aggregate market value of $150,144.48. The filing notes that 23,678,745 shares of common stock were outstanding when the notice was prepared.
The seller acquired the 3,048 shares on 11/25/2025 by exercising stock options granted by the issuer and paid the purchase price in cash on the same date. The Form 144 also includes the standard representation that the seller does not know of any undisclosed material adverse information about Proto Labs’ current or prospective operations.
Proto Labs, Inc. (PRLB) reported an insider equity award for its Chief Technology & AI Officer on a Form 4. On 11/17/2025, the officer received 3,718 shares of common stock as a restricted stock unit grant at a price of $0, increasing direct beneficial ownership to 3,718 shares. The filing also reports a grant of an employee stock option for 6,818 shares of common stock with a $47.07 exercise price, expiring on 11/17/2035.
The restricted stock units vest annually over four years starting on November 15, 2026, and the stock option vests on the same schedule. This structure is designed so that the officer earns the awards gradually over time, which can help align long-term incentives with company performance and retention.
Disciplined Growth Investors, Inc. filed Amendment No. 6 to a Schedule 13G reporting beneficial ownership of 2,592,373 Proto Labs (PRLB) common shares, representing 10.9% of the class as of 09/30/2025.
The filer reports sole voting power over 2,316,889 shares and sole dispositive power over 2,592,373 shares, with no shared voting or dispositive power. The reporting person is classified as an investment adviser (IA).
In its certification, the filer states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Proto Labs.
PRLB filed a Form 144 for a proposed sale of 9,710 common shares, with an aggregate market value of $471,629.27. The shares may be sold through Morgan Stanley Smith Barney LLC, with an approximate sale date of 11/07/2025 on the NYSE. The securities were acquired primarily via restricted stock vesting under a registered plan and an employee stock purchase plan, including tranches such as 1,567 shares vested on 02/13/2024 and 797 shares purchased on 11/15/2023.
Proto Labs (PRLB) reported Q3 2025 results. Revenue rose to $135.366M from $125.619M (up 7.8%). Diluted EPS was $0.30 versus $0.29 a year ago. Gross margin was 45.3% compared with 45.6% last year as higher volumes were offset by increased personnel and production costs. Operating income was $8.810M and net income was $7.216M.
Growth was led by the U.S. segment, where revenue increased 9.8% to $109.361M, while Europe was essentially flat at $26.005M. By product line, CNC Machining grew 18.2% to $63.043M, Injection Molding rose 2.0% to $47.770M, Sheet Metal increased 13.9% to $4.262M, and 3D Printing declined 6.3% to $20.082M. The company served 21,252 customer contacts in Q3 (down 5.6%), while revenue per contact rose 14.1%.
Year-to-date revenue reached $396.634M (up 4.6%). Cash and cash equivalents were $104.422M as of September 30, 2025. Operating cash flow for the first nine months was $58.053M. The company repurchased $36.732M of common stock year-to-date. Shares outstanding were 23,678,745 as of October 28, 2025.
Proto Labs, Inc. (PRLB) furnished an 8-K announcing its third quarter 2025 financial results. The company reported the news via a press release that is attached to the filing as Exhibit 99.1 and incorporated by reference.
The filing is administrative in nature and points readers to the press release for the full results.
Proto Labs (PRLB) filed an initial Form 3 for a new executive. The reporting person serves as Chief Technology & AI Officer and indicated no securities are beneficially owned.
The filing was made by one reporting person and includes a Power of Attorney as an exhibit.
Proto Labs, Inc. reported a leadership change in its technology organization. On October 3, 2025, the company announced that Chief Technology Officer Oleg Ryaboy will depart and cease to be an employee effective November 2, 2025, and is no longer an executive officer as of that notice date.
Marc Kermisch has been appointed as the new Chief Technology & AI Officer, effective October 13, 2025, marking a transition that adds explicit responsibility for artificial intelligence. Upon departure, Mr. Ryaboy will receive severance benefits under the company’s existing Form of Executive Severance Agreement. The company also issued a press release detailing this leadership transition.
Disciplined Growth Investors, Inc. reports beneficial ownership of 2,722,011 shares of Proto Labs Inc. common stock, representing 11.4% of the outstanding class. The filer states it has sole voting power over 2,446,527 shares and sole dispositive power over all 2,722,011 shares, and that the securities were acquired and are held in the ordinary course of business rather than to influence control. The filing lists the issuers principal office in Maple Plain, Minnesota, and the reporting persons office in Minneapolis. The statement is signed by the firm's Chief Compliance Officer on 08/14/2025.